Cartesian Therapeutics Inc. (RNAC) — Cash Flow-to-Debt Ratio
Cartesian Therapeutics Inc. (RNAC) has a Cash Flow-to-Debt Ratio of -0.05x as of March 2026, meaning its operating cash flow of $-22.14 Million could theoretically repay 0% of its total liabilities ($436.51 Million) in one year. See Cartesian Therapeutics Inc. free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cartesian Therapeutics Inc. Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Cartesian Therapeutics Inc. across 12 annual periods. For the full cash flow conversion analysis, see Cartesian Therapeutics Inc. cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Cartesian Therapeutics Inc. (2014–2025)
Year-by-year debt coverage analysis for Cartesian Therapeutics Inc.. Check Cartesian Therapeutics Inc. cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.17x | $-73.94 Million | $422.65 Million | ▼ -226.5% |
| 2024 | -0.05x | $-23.67 Million | $441.82 Million | ▲ +21.9% |
| 2023 | -0.07x | $-51.16 Million | $745.23 Million | ▲ +84.4% |
| 2022 | -0.44x | $-31.63 Million | $72.06 Million | ▲ +0.1% |
| 2021 | -0.44x | $-60.38 Million | $137.36 Million | ▼ -331.2% |
| 2020 | 0.19x | $34.88 Million | $183.44 Million | ▲ +133.7% |
| 2019 | -0.56x | $-51.44 Million | $91.17 Million | ▲ +52.4% |
| 2018 | -1.19x | $-59.16 Million | $49.90 Million | ▼ -12.3% |
| 2017 | -1.06x | $-52.04 Million | $49.29 Million | ▼ -84.2% |
| 2016 | -0.57x | $-19.68 Million | $34.34 Million | ▼ -306.5% |
| 2015 | -0.14x | $-22.46 Million | $159.32 Million | ▼ -22.2% |
| 2014 | -0.12x | $-12.69 Million | $109.98 Million | — |